Riskpilot← Back to searchSign inGet full accessAprea Therapeutics AB
ABActiveOrg 5566312285MärstaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20021 employees
Revenue 2024
SEK 0
EBITDA margin
—
+56% vs 2023
Equity ratio
8.4%
Financial strength
Net profit 2024
SEK -2,3M
+57% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -2,5M | +56% |
| Net profit | SEK -2,3M | +57% |
| Total assets | SEK 7,8M | -56% |
| Equity | SEK 655K | -93% |
| Employees | 1 | — |
Legal name
Aprea Therapeutics AB
Org number
5566312285
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 september 2002
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Gilad, Oren
Company purpose
Bolaget ska bedriva forsknings-, utvecklings-, försäljnings- och licensieringsverksamhet inom läkemedelsområdet och därmed förenlig verksamhet, samt förvalta fast och lös egendom och idka därmed förenlig verksamhet.
Address
Märsta
Phone
+46705755509
Email
kimmo.sinervo@aprea.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 159 | 165 | 191 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −194 545 | −114 236 | −61 903 | −5 662 | −2 519 |
| Depreciation & amort. | −110 | −69 | −45 | −0 | −0 |
| EBIT | −194 655 | −114 305 | −61 948 | −5 662 | −2 519 |
| Net financials | −8 206 | 2 724 | 22 | 270 | 214 |
| Profit before tax | −202 861 | −111 581 | −61 926 | −5 392 | −2 305 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −202 861 | −111 581 | −61 926 | −5 392 | −2 305 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 167 645 | 60 714 | 17 860 | 17 503 | 7 787 |
| Equity | 76 236 | 16 745 | 8 352 | 9 518 | 655 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 88 338 | 42 883 | 9 508 | 7 986 | 7 133 |
| Total debt | 88 338 | 42 883 | 9 508 | 7 986 | 7 133 |
EBITDA margin
-251900000.0%
This company
15.8%
Market median
-1594303897% vs market
20202024
Equity ratio
8.4%
This company
38.2%
Market median
-78% vs market
20202024
Return on equity
-351.9%
This company
18.4%
Market median
-2013% vs market
20202024
Net profit margin
-230500000.0%
This company
8.1%
Market median
-2845679112% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
10.89×
This company
0.62×
Market median
-1656% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LM Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
FO Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
APREA THERAPEUTICS INC
Aprea Therapeutics AB (this company)Aprea Us IncAPREA US INCBoard members of Aprea Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fredrik Oskar Norrman | Chief Auditor | 0 companies |
| Linn Maria Haslum Lindgren | Chief Auditor | 0 companies |
| Kimmo Kalervo Sinervo | Deputy Board Member | 0 companies |
| Lars Bertil Abrahmsén | Board of Directors | 0 companies |
| Oren Gilad | Chairman | 0 companies |